… progress is an unmet clinical need. Regardless of aetiology, those with advanced liver
fibrosis have been observed to be at a greater risk of developing adverse clinical events and …

… fibrosis (F2-F4) or advanced fibrosis (F3-F4). The use of plasma or serum for biomarker analysis
… the efficacy of low-cost serum fibrosis biomarkers in the prediction of not only advanced …

… endpoint in clinical studies for antifibrotic drugs (21). … of liver fibrosis and antifibrotic drugs
that can reduce advanced … activation and collagen deposition, thereby causing liver fibrosis (80)…

… liver disease (NAFLD) are at risk of developing advanced … , noninvasive biomarkers for the
diagnosis of liver fibrosis have … amounts of fibril-forming collagens) is the dominant event in …

… blood biomarker (BARD or AST/ALT ratio), found a normal blood biomarker excluded 12% of
patients with liver disease … of collagen synthesis which is overexpressed in the presence of …

… Several publications have shown in multiple animal models of liver fibrosis that collagen VI
… disease patients likely to regress or progress in absence of any therapeutic intervention. Only …

… Although not yet used in routine clinical practice, advances in … features of fibrosis at the
individual collagen fiber level. … biomarkers, such as fibrosis-4 (FIB-4) index, NAFLD fibrosis …

… advance the research on the discovery of clinically significant biomarker candidates for
liver fibrosis … As the rate of collagen synthesis plays a major role in any tissue fibrosis [155,156] …

… decreased fibrosis-related markers and biomarkers in … I collagen in mice with hepatic fibrosis
induced by CCl 4 . Moreover, MiR-29b dramatically prevented the progress of liver fibrosis …

… OPN delayed resolution of liver fibrosis because of sustained deposition of collagen-I, as …
-invasive biomarker for complications of advanced liver disease. Up to now in routine clinical …